Wanbury Ltd Hits All-Time High of Rs 352.95 as Momentum Builds Across Timeframes

1 hour ago
share
Share Via
Extending a remarkable five-day winning streak, Wanbury Ltd surged to a fresh all-time high of Rs 352.95 on 15 Jul 2026, outperforming its sector and the broader market with a 5.19% gain on the day.
Wanbury Ltd Hits All-Time High of Rs 352.95 as Momentum Builds Across Timeframes

Record-Breaking Price Movement

On 15 July 2026, Wanbury Ltd’s share price surged to Rs.352.95, setting a new 52-week and all-time high. The stock opened with a gap-up of 2.16% and closed the day with a gain of 5.19%, significantly outperforming the Sensex, which recorded a modest 0.74% increase. Intraday volatility was notably high at 22.77%, reflecting active trading and investor engagement throughout the session.

The stock has been on a strong upward trajectory, registering gains for five consecutive days and delivering a cumulative return of 29.74% during this period. Over the past week, Wanbury Ltd outperformed its sector by 3.19%, underscoring its relative strength within the Pharmaceuticals & Biotechnology space.

Comparative Performance Against Benchmarks

Wanbury Ltd’s recent performance stands out when compared with broader market indices. Over the last one year, the stock has appreciated by 30.46%, while the Sensex declined by 5.99%. Year-to-date, the stock has surged 55.65%, contrasting with the Sensex’s fall of 8.92%. Longer-term returns are even more striking, with a three-year gain of 613.09% against the Sensex’s 17.50%, and a ten-year return of 784.98% compared to the Sensex’s 178.85%.

This consistent outperformance highlights Wanbury Ltd’s ability to generate substantial shareholder value over extended periods, reflecting both operational execution and market confidence.

Technical Indicators Confirm Bullish Momentum

The technical outlook for Wanbury Ltd remains strongly bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. Key technical indicators such as MACD, Bollinger Bands, and Dow Theory are aligned with a positive trend on both weekly and monthly timeframes.

Immediate support is established at Rs.162.00, the 52-week low, while resistance levels have been surpassed, with the stock now approaching the 52-week high of Rs.360.00. Delivery volumes have surged, with a 1-day delivery change of 1057.89% compared to the 5-day average, indicating strong participation from market participants.

Financial Strength and Profitability Metrics

Wanbury Ltd’s financial performance underpins its stock price appreciation. The company has reported positive results for four consecutive quarters, with operating profit to interest ratio reaching a quarterly high of 3.70 times. Quarterly PBDIT peaked at Rs.29.85 crores, while operating profit to net sales ratio hit 18.14%, reflecting efficient cost management and profitability.

Return on capital employed (ROCE) stands at an attractive 33.3%, complemented by a strong return on equity (ROE) of 42.23%. These metrics indicate effective utilisation of capital and robust earnings generation capacity.

Valuation and Growth Dynamics

Despite the recent rally, Wanbury Ltd trades at a reasonable valuation relative to its growth profile. The price-to-earnings (P/E) ratio is 27x, with a price-to-book value (P/BV) of 19.81x. The enterprise value to capital employed ratio is a moderate 6.00x, suggesting an attractive valuation compared to peers’ historical averages.

The company’s PEG ratio of 0.24x indicates that earnings growth is outpacing the stock price increase, signalling potential value for investors focused on growth metrics. Operating profit has grown at an annualised rate of 62.06%, while net sales have expanded at 10.62% annually over the past five years.

Quality Assessment and Capital Structure

Wanbury Ltd is classified as an average quality company based on long-term financial performance. While growth metrics and returns on capital are strong, the company carries a relatively high debt burden, with an average debt-to-equity ratio of 3.36 times and net debt to equity of 2.77 times. This leverage level is a factor to consider in assessing financial risk.

Promoter shareholding is substantial, with 86.69% of promoter shares pledged, which may exert pressure on the stock in volatile market conditions. Institutional holdings remain low at 0.59%, reflecting limited participation from large institutional investors.

Consistent Returns Over Multiple Time Horizons

Wanbury Ltd has demonstrated consistent returns across various time frames. The stock has outperformed the BSE500 index in each of the last three annual periods, reinforcing its status as a strong performer within the mid and small-cap universe. The five-year return of 303.14% further attests to the company’s sustained growth trajectory.

These returns are supported by solid fundamentals, including a sales to capital employed ratio of 2.95x and a tax ratio that, while negative, has not impeded profitability growth.

Summary of Key Financial and Market Metrics

As of 15 July 2026, Wanbury Ltd’s stock price stood at Rs.352.95, close to its 52-week high of Rs.360.00. The stock’s market capitalisation classifies it as a micro-cap entity within the Pharmaceuticals & Biotechnology sector. The company’s mojo score improved to 71.0, with a recent upgrade from Hold to Buy on 14 July 2026, reflecting enhanced market sentiment and fundamental strength.

Dividend yield data is not available, with the latest dividend declared at Rs.1 per share and an ex-dividend date dating back to 2010. The company’s valuation multiples and financial ratios suggest a balanced profile of growth and risk.

Conclusion: A Milestone Reflecting Strong Performance

Wanbury Ltd’s attainment of an all-time high share price of Rs.352.95 on 15 July 2026 is a testament to its sustained operational performance, robust profitability, and consistent market outperformance. The stock’s strong technical indicators, healthy financial metrics, and impressive long-term returns underscore the company’s position as a noteworthy player in the Pharmaceuticals & Biotechnology sector.

While the company carries elevated leverage and a high proportion of pledged promoter shares, its growth in operating profit, attractive returns on capital, and valuation metrics provide a comprehensive picture of a firm that has successfully navigated its growth journey to reach this significant milestone.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News